2021年非小细胞肺癌重要临床研究纵观与解读

An Overview and Interpretation of Important Clinical Studies on Non-small Cell Lung Cancer in 2021

尽管2021年新冠病毒仍在肆虐,非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床研究并未止步。得益于肺癌治疗模式的进步,NSCLC患者的总生存时间和生活质量得到了显著改善。目前靶向治疗与免疫治疗的研究进展改变了术后辅助治疗的现状,建立了可手术NSCLC治疗新标准。局部晚期和晚期NSCLC同样有重要的研究进展,包括新的治疗模式、新的治疗药物等,均为临床治疗带来更多选择。相信在可预见的未来,这些疗法都将为NSCLC的治疗带来改变,并逐步走向肺癌“慢病化”的道路。因此,本文简要综述了2021年改变肺癌治疗临床实践的重要研究以及值得关注的研究进展。

Though the coronavirus disease is still raging in 2021,clinical research on non-small cell lung cancer(NSCLC)did not stop.However,benefiting from advances in lung cancer treatment modality,NSCLC patients have experienced significant improvements in overall survival and quality of life.Currently,research advances on targeted therapy and immunotherapy have together transformed the status of postoperative adjuvant therapy and established a new standard treatment modality for resectable NSCLC.There are equally important research advances in locally advanced and advanced NSCLC,including new treatment modalities,new therapeutic agents,etc.,all of which bringing more options for clinical treatment.These therapies will bring changes to NSCLC and will gradually lead to the chronicity of lung cancer in the foreseeable future.Therefore,this paper reviews important studies that will change clinical practice in NSCLC treatment and noteworthy research advances in 2021.